Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bruk av transkraniell fotobiomodulering for å forbedre kognisjon og selvrapporterte resultater hos overlevende av barnekreft

1. oktober 2026 oppdatert av: St. Jude Children's Research Hospital

Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning.

Primary Objective

To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL.

Secondary Objectives

To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL.

Exploratory Objectives

To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.

Studieoversikt

Detaljert beskrivelse

Survivors with ALL and HL with identified executive function impairment will be randomized to receive stimulation with alpha tPBM + cognitive training, gamma tPBM + cognitive training or sham tPBM + cognitive training three days per week for a 2-month intervention period The tPBM will be applied to nodes in the default mode network.

Studietype

Intervensjonell

Registrering (Faktiske)

44

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Tennessee
      • Memphis, Tennessee, Forente stater, 38105
        • St. Jude Children's Research Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Completed treatment for acute lymphoblastic leukemia (ALL) or Hodgkin's Lymphoma (HL) at SJCRH.
  • Enrolled in SJLIFE, and less than 21 years of age at diagnosis.
  • 18 years of age or older at time of enrollment.
  • 2 years or greater post-treatment completion of cancer directed therapy and not currently receiving any cancer directed therapy.
  • English language proficiency.
  • Access to WiFi.
  • Executive dysfunction defined as having an age-adjusted standard score less than 16th percentile on objectively assessed cognitive test or patient-reported executive dysfunction defined as having a standard score greater than 84th percentile within 3 years of time of enrollment.

Exclusion Criteria:

  • Estimated intelligence score less than 80.
  • Currently taking medication intended to treat neurocognitive impairment (i.e., stimulants).
  • Major psychiatric condition.
  • Alcohol abuse in the past year (AUDIT) [greater than or equal to 13 for women and greater than or equal to 15 for men]. The Alcohol Use Disorders Identification Test (AUDIT) will be used to screen for individuals who have active alcohol-use disorders.
  • Drug abuse in the past year (DAST-10) [ greater than or equal to 3 for women or men] The Drug Abuse Screen Test (DAST-10) will be used to screen for individuals with active drug abuse.
  • History of neurologic condition or genetic disorder associated with neurocognitive impairment unrelated to cancer diagnosis or treatment.
  • Enrolled on another independent cognitive intervention protocol within the last year.
  • Female participants who are pregnant or lactating (determined by participant self-report due to the remote nature of this study)
  • Tattoo or artificial marking in the area where the device will be positioned.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: Randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: alpha tPBM + cognitive training

three days per week for a 2-month intervention period (5 ALL and 5 HL)

The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.

Andre navn:
  • Vielight bærbar tPBM NeURO-enhet.
Eksperimentell: gamma tPBM + cognitive training

three days per week for a 2-month intervention period (5 ALL and 5 HL)

The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.

Andre navn:
  • Vielight bærbar tPBM NeURO-enhet.
Eksperimentell: sham tPBM + cognitive training

Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL)

The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.

Andre navn:
  • Vielight bærbar tPBM NeURO-enhet.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants who completed a two-month trial of paired photobiomodulation (PBM) therapy and cognitive training
Tidsramme: 4 months after participant enrollment

The trial will be considered feasible if at least 15 of 30 survivors are able to complete 18 of 24 sessions (PBM along with cognitive training).

4 months after participant enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
CNS Vital Signs adaptions of the Rey auditory verbal learning test (RVLT).
Tidsramme: 2 month and 4 months after enrollment

RVLT is a test that evaluate working memory.

2 month and 4 months after enrollment
CNS Vital Signs adaptions of the Rey visual design learning (RVDL) test.
Tidsramme: 2 month and 4 months after enrollment

RVDL is a test that evaluate working memory.

2 month and 4 months after enrollment
CNS Vital Signs implemented Stroop color and word test.
Tidsramme: 2 month and 4 months after enrollment

The Stroop test is a test that evaluates Inhibitory control.

2 month and 4 months after enrollment
CNS Vital Signs implemented Shifting Attention Test.
Tidsramme: 2 month and 4 months after enrollment

The Shifting attention test and Stroop test are tests that are used to measure cognitive flexibility.

2 month and 4 months after enrollment
CNS Vital Signs implementation of the Continuous Performance Test (CPT).
Tidsramme: 2 month and 4 months after enrollment

The CPT test is a test that evaluates attention.

2 month and 4 months after enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nicholas Phillips, MD,PhD, St. Jude Children's Research Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. januar 2023

Primær fullføring (Faktiske)

6. juni 2025

Studiet fullført (Faktiske)

9. juli 2026

Datoer for studieregistrering

Først innsendt

19. september 2022

Først innsendt som oppfylte QC-kriteriene

21. september 2022

Først lagt ut (Faktiske)

22. september 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • PBMP
  • NCI-2022-09116 (Annen identifikator: NCI Clinical Trial Registration Program)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere